Arena Pharmaceuticals announced the initiation of dosing in a Phase 1 clinical trial of APD811 for the treatment of pulmonary arterial hypertension (PAH). This randomized, double-blind and placebo-controlled Phase 1 trial is planned to enroll up to 72 healthy adult volunteers and will evaluate the safety, tolerability and pharmacokinetics of single-ascending doses of APD811.
APD811 is a potent and selective prostacyclin receptor agonist. Prostacyclin receptor agonists, through regulation of vascular smooth muscle tone, improve mortality and exercise tolerance in PAH patients. Currently available prostacyclin receptor agonists belong to the prostanoid class of molecules and these products need to be administered frequently or continuously through intravenous, subcutaneous or inhaled routes. APD811 is a non-prostanoid prostacyclin agonist and is orally bioavailable.
For more information call (858) 453-7200 or visit www.arenapharm.com.